iRhythm Technologies 株価情報 (NASDAQ: IRTC)

iRhythm Technologies (NASDAQ:IRTC) 株価情報

IRHYTHM TECHNOLOGIES INC

iRhythm Technologies

iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

News

Movers

AMKR

BILI

BRFS

IBRX

IRTC

ITCI

OLLI

RKLB

TALO

これらの中型株は先週最も楽観的なパフォーマンスを示しました。あなたのポートフォリオには入っていますか？Bilibili Inc.は（NASDAQ：BILI）は、先週「三國：謀定天下」の発売以降23.32%上昇しました。さらに、JPモルガン（JP Morgan）のアナリスト、ダニエル・チェン氏はBilibiliの株をニュートラル（中立評価）からオーバーウェイト（買い評価）に格上げし、21ドルの株価予測を発表しました。

中国配信大手ビリビリ　株価が23%の高騰

ACLS

AGIO

HALO

LBTYB

LEGN

NEOG

NUVL

NVAX

NVDA

SMAR

TWST

VRNT

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？

直近1週間高パフォーマンスを示したのは、中型株

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies Inc

Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) has outperformed the market over the past 15 years by 17.18% on an annualized basis producing an average annual return of 29.38%. Currently, Cadence Design Systems has a market capitalization of $80.46 billion. 
Buying $100 In CDNS: If an investor had bought $100 of CDNS stock 15 years ago, it would be worth $4,777.36 today based on a price of $293.33 for CDNS at the time of writing.
<h3>Cadence Design Systems's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748990718_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CDNS

Here's How Much $100 Invested In Cadence Design Systems 15 Years Ago Would Be Worth Today

"Why do we feel so poor?" That's the question that launched one of the most relatable rants in the <a href="https://www.reddit.com/r/MiddleClassFinance/s/ZE5IKPT0GY">r/MiddleClassFinance subreddit</a> — and it wasn't some vague complaint. It came with receipts.&nbsp;
The original poster opened with a stat that sounds almost unbelievable: "Every state in the US has a higher median income than the UK." Yet somehow, they wrote, "we feel like it's not enough."
"We're making more, most of our costs are lower, taxes are lower," they said. "How do people in the UK survive on so little when food, housing, and transportation costs more over there?"
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
It's the kind of post that feels like it came from the dinner table after a long day of paying for things — groceries, childcare, student loans, and another unexpected dentist bill — and still feeling like you're behind. And then came the part that hit a little harder: "If the US is a third world country, where else is it better?"
The poster wasn't just venting. They were pointing out what looked like a contradiction. If Americans earn more and spend less — at least on paper — why does everything still feel like a financial uphill climb? They even argued that America has a leg up when it comes to early retirement, writing, "I've never heard of anyone in the middle class in other countries be <a href="https://www.benzinga.com/personal-finance/25/03/44552100/i-have-no-doubt-theyre-going-to-raise-the-full-retirement-age-possibly-to-70-suze-orman-weighs-in-on-social-security-fears">able to retire in their 40s</a> or early 50s, yet it's very possible here in America."
So, are they right?
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
Statistically, yes. Median household income in the U.S. was $74,580 as of the most recent <a href="https://www.census.gov/library/publications/2023/demo/p60-279.html">census data</a>. In the UK, <a href="https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/bulletins/annualsurveyofhoursandearnings/2023">it's around £34,963</a> ($44,400). Even the lowest-earning U.S. states like Mississippi still come out ahead in raw income.
But that's where the logic starts to fray.
One Redditor who had lived in both countries chimed in with what seemed like the missing piece: "In the UK, people make it work on less not because life is cheaper… but because the government fills in more of the gaps." Healthcare is free at the point of use. Public transit is subsidized. Childcare isn't a second rent payment. And while rent and food can be expensive, there's at least a safety net to catch people when they fall.
Over in the U.S., falling can mean falling hard. Another user, a business owner, broke it down like this: "We directly pay $45k a year for insurance that by US standards is on the ‘better' end… and we have to budget about 10k a year for medical expenses." They also had two kids attending public universities in Texas — "reasonable" by U.S. standards — but still, "it's 50k out the door to pay for it."
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
They described themselves as higher earners, but said, "This is a hit. There are zero social safety nets in my state."
So yes, <a href="https://www.benzinga.com/personal-finance/25/04/44891276/the-average-household-is-a-millionaire-with-a-1-06-million-net-worth-according-to-the-fed-so-why-do-people-still-feel-broke">Americans might earn more</a>. But they're also covering more ground alone. Income doesn't equal insulation. And that's the nuance buried under the numbers. One medical emergency, one layoff, one school bill too big to split — and suddenly, that higher income doesn't feel like it buys you much at all.
It's not that the original post was wrong — if anything, it might've understated the issue. Americans do make more. Things do cost less. But many still feel poor because, frankly, they're carrying the cost of survival without the stabilizers. When nothing is guaranteed — not health care, not housing, not education — that "<a href="https://www.benzinga.com/personal-finance/25/05/45483330/are-you-rich-or-just-upper-middle-class-heres-the-net-worth-and-income-it-takes-to-be-considered-wealthy">higher median income</a>" doesn't feel like wealth. It just feels like a number that doesn't tell the whole story.
And if people making more in every state still feel like they're just barely staying afloat? That probably answers the question better than any chart ever could.
Read Next:
<ul class="wp-block-list">
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>
Image: Shutterstock

Personal Finance

'Why Do We Feel So Poor?' —Middle-Class American Says Every U.S. State Pays More Than the UK And We Have Lower Costs, Yet Brits Still Live Better

Kinross Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) has outperformed the market over the past 5 years by 6.97% on an annualized basis producing an average annual return of 19.99%. Currently, Kinross Gold has a market capitalization of $19.10 billion. 
Buying $100 In KGC: If an investor had bought $100 of KGC stock 5 years ago, it would be worth $249.52 today based on a price of $15.57 for KGC at the time of writing.
<h3>Kinross Gold's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748989813_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Kinross Gold 5 Years Ago Would Be Worth Today

A congressman has disclosed buying Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) on four occasions in 2025, with some of the trades happening past the 45-day window, adding to the recent <a href="https://www.benzinga.com/politics/25/04/45077654/bill-named-after-nancy-pelosi-could-ban-congress-members-from-trading-stocks-what-you-need-to-know-about-the-pelosi-act">calls to ban members</a> of Congress from buying and selling stocks and other investments.
What Happened: A bill that would ban members of Congress from buying stocks and options may not apply to cryptocurrency purchases, which could be good news for members <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45018551/senator-on-digital-assets-committee-buys-more-bitcoin-etf-shares-2025-is-the-year-for-digital-assets">who have bought</a> Bitcoin, meme coins and Bitcoin ETFs.
Rep. Brandon Gill (R-Texas), a close ally of President Donald Trump, is the latest member of Congress to disclose buying cryptocurrency.
Gill disclosed the following Bitcoin purchases, with their transaction dates listed below:
<ul class="wp-block-list">
<li>Jan. 29, 2025: $100,000 to $250,000 BTC</li>
<li>Feb. 27, 2025: $100,000 to $250,000 BTC</li>
<li>May 13, 2025: $100,000 to $250,000 BTC</li>
<li>May 18, 2025: $50,000 to $100,000 BTC</li>
</ul>
In total, Gill has added between $350,000 and $850,000 in Bitcoin to his investment portfolio, with the trades tracked by <a href="https://www.benzinga.com/gov-trades/members/brandon-gill">Benzinga's Government Trades page</a>.
The big problem with the disclosure is that Gill didn't disclose the January and February purchase until now, which is far beyond the 45-day window members of Congress have to make disclosures.
"Congressman Gill bought $850k worth of Bitcoin this year, $BTC. Also broke the law reporting this late," Congresstrading <a href="https://x.com/congresstrading/status/1929996331088486735">tweeted</a>.
Gill's trades are mostly close to being even with the current price of Bitcoin as the leading cryptocurrency trading at over $100,000 on Jan. 29, May 13 and May 30. The exception would be the trade on Feb. 27, which was made when Bitcoin traded between $83,144.96 and $87,000.78 on the day.
The timing of Gill's trades is drawing more attention, given his close ties to Trump. The Jan. 29 trade was shortly after Trump's executive order for the U.S. to be a leader in digital assets and the Feb. 27 purchase was just ahead of Trump announcing a "strategic Bitcoin reserve."
Did You Know?
<ul class="wp-block-list">
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent060325">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Members of Congress have received fines of $200 in the past for not disclosing their trades on time, an amount that has helped push the call for a ban of Congress&#8217;s trading activity.
Other members of Congress have made questionable trades in cryptocurrency like Bitcoin and Bitcoin ETFs around Trump announcements, which could prompt calls for a ban on buying and selling cryptocurrency for Congress members as well.
Right now, the proposed P.E.L.O.S.I. Act does not mention cryptocurrency.
Benzinga <a href="https://www.benzinga.com/25/05/45594252/exclusive-no-hodling-for-congress-48-say-elected-members-shouldnt-be-able-to-buy">recently polled readers</a> on the trading activity of members of Congress.
&#8220;Should members of Congress be allowed to invest in cryptocurrency?&#8221; we asked. Here are the results:
<ul class="wp-block-list">
<li>No, they shouldn&#8217;t be able to invest in cryptocurrencies: 48%</li>
<li>Yes, as long as they disclose: 30%</li>
<li>Yes, but through ETFs and not actual cryptocurrencies: 15%</li>
<li>Yes, they don&#8217;t need to disclose: 8%</li>
</ul>
The poll found that nearly half of voters said that members of Congress shouldn&#8217;t be able to invest in cryptocurrency. Only 30% supported the current method of allowing them to invest as long as they disclose.
Eight percent said let Congress members buy and sell cryptocurrency without needing to disclose.
Ranking third was yes to investing, but doing so through ETFs like the&nbsp;iShares Bitcoin ETF Trust&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>).
Investing in cryptocurrency such as Bitcoin has become more mainstream for members of Congress, but the public could view investments in &#8220;meme coins,&#8221; especially some obscure cryptocurrencies, as questionable.
Rep. Mike Collins&nbsp;(R-Ga.)<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42330146/congressman-buys-meme-coins-ski-mask-dog-coin-climbs-in-value-after-disclosure-i-liked-the-coins-so-i-bought-them" target="_blank" rel="noreferrer noopener">&nbsp;previously disclosed buying</a>&nbsp;Ski Mask Dog&nbsp;(CRYPTO: SKI). The crypto spiked after the disclosure went viral on social media and Collins bought more later.
Trump has been supportive of a potential ban on members of Congress buying and selling stocks and options. Trump has not mentioned banning cryptocurrency trades, which comes as the president has his own Official Trump Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) and has been supportive of the cryptocurrency sector.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank">Top 10 Stock Traders In Congress For 2024: How Nancy Pelosi, Pete Sessions, Susan Collins, Marjorie Taylor Greene Rank</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Politics

$BTC

$TRUMP

IBIT

Congressman Buys Up To $850K In Bitcoin In 2025: Late Disclosure, Close Trump Ties Wave Red Flags

HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) has outperformed the market over the past 10 years by 17.07% on an annualized basis producing an average annual return of 28.14%. Currently, HubSpot has a market capitalization of $31.65 billion. 
Buying $1000 In HUBS: If an investor had bought $1000 of HUBS stock 10 years ago, it would be worth $11,966.30 today based on a price of $600.11 for HUBS at the time of writing.
<h3>HubSpot's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748988912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HUBS

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Wells Fargo &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares are rising in Tuesday&#8217;s after-hours session after the company announced it&#8217;s no longer subject to asset growth restrictions<a href="https://www.benzinga.com/government/20/03/15485764/house-report-says-wells-fargo-continues-to-abuse-customers-blasts-regulators-for-inaction"> imposed in 2018</a>.
What Happened: Wells Fargo said the board of governors of the Federal Reserve determined that Wells Fargo has met all conditions required to remove the limits on growth in total assets imposed in its 2018 consent order.
&#8220;The Federal Reserve&#8217;s decision to lift the asset cap marks a pivotal milestone in our journey to transform Wells Fargo. We are a different and far stronger company today because of the work we&#8217;ve done,&#8221; said Charlie Scharf, CEO of Wells Fargo.
&#8220;In addition, we have changed and simplified our business mix, and we have transformed the management team and how we run the company. We have been methodically investing in the company&#8217;s future while improving our financial results and profile.&#8221;
<h1 class="wp-block-heading">Is WFC A Good Stock To Buy?</h1>
An investor or trader's decision to buy or sell a stock is unique to their time horizon and risk tolerance. Many typical investors evaluate earnings growth and valuation on a particular stock before making a decision. 
For example, with Wells Fargo, you'll notice earnings in its last quarter <a href="https://www.benzinga.com/quote/WFC/earnings">grew 2.42%</a>. As an investor, you'll want to decide whether that's better or worse than what you'd like to see among stocks in your portfolio.
On the valuation side, Wells Fargo's price to earnings ratio — a measure of how much an investor pays for the company's earnings — is projected to grow 15.77% in the current quarter when compared to last year. That places it above similar businesses JPMorgan Chase, Bank of America and HSBC Holdings in its sector. You'll need to decide whether that makes it more or less attractive based on how you think the company will perform over time.
There are many different valuation metrics that may help you make a decision. Find more on <a href="https://www.benzinga.com/quote/WFC">Wells Fargo's quote page</a>, or if you'd like a deeper dive in an advanced program, try <a href="https://pro.benzinga.com">Benzinga PRO</a> for free.
WFC Price Action: <a href="http://benzinga.com/quote/WFC">Wells Fargo shares</a> were up 2.67% in after-hours, trading at $77.67 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45758298/april-inflation-print-was-the-last-vestige-of-pre-tariff-impact-feds-goolsbee-says">April Inflation Print Was The &#8216;Last Vestige&#8217; Of Pre-Tariff Impact, Fed&#8217;s Goolsbee Says</a></li>
</ul>
Photo: Bumble Dee/Shutterstock.

Federal Reserve

After-Hours Center

Wells Fargo Stock Is Rising After Hours: What's Going On?

Macro Economic Events

Econ #s

Economics

USA API Weekly Crude Oil Stock 3.3M Barrel Draw Vs 0.900M Barrel Draw Est.; 4.236M Barrel Draw Prior

In the current session, the stock is trading at $78.70, after a 1.72% spike. Over the past month, Mueller Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>) stock increased by 6.58%, and in the past year, by 38.92%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1748988022_0.png" alt="Past Year Chart" />

<h3>Mueller Industries P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Mueller Industries has a lower P/E than the aggregate P/E of 27.71 of the Machinery industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748988022_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: Mueller Industries

Analysts' ratings for Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.0, a high estimate of $30.00, and a low estimate of $26.00. This upward trend is apparent, with the current average reflecting a 3.7% increase from the previous average price target of $27.00.
<img src="https://www.benzinga.com/files/images/story/2025/1748988017_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Kinder Morgan. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Brandon Bingham</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kinder Morgan. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kinder Morgan compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Kinder Morgan's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Kinder Morgan's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KMI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kinder Morgan analyst ratings.</a>
<h2>Get to Know Kinder Morgan Better</h2>
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 80,000 miles of gas, refined products, and carbon dioxide pipelines. The company also owns one of the largest portfolios of gas and refined products storage and terminals. Most of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
<h3>Kinder Morgan's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3M period, Kinder Morgan showcased positive performance, achieving a revenue growth rate of 10.39% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Kinder Morgan's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.81%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Kinder Morgan's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.33%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Kinder Morgan's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.99%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.07, Kinder Morgan adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Kinder Morgan: Insights From 4 Analyst Reviews

Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) has outperformed the market over the past 20 years by 11.93% on an annualized basis producing an average annual return of 20.26%. Currently, Quanta Services has a market capitalization of $52.85 billion. 
Buying $100 In PWR: If an investor had bought $100 of PWR stock 20 years ago, it would be worth $3,974.25 today based on a price of $356.49 for PWR at the time of writing.
<h3>Quanta Services's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748988016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Quanta Services 20 Years Ago Would Be Worth Today

Offerings

Dorian LPG Files For Potential Mixed Shelf; Size Not Disclosed

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 15 years by 9.69% on an annualized basis producing an average annual return of 21.89%. Currently, Regeneron Pharmaceuticals has a market capitalization of $52.77 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $1,840.98 today based on a price of $488.79 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748987111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REGN

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years

Rumors

Watching Trump Media & Technology Group; Traders Circulate President Trump's Truth Social Files For A Bitcoin ETF

<a href="https://x.com/seckennedy/status/1930012848056365294?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/seckennedy/status/1930012848056365294?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

General

BNTX

MRNA

US Health Secretary Kennedy Posts On X "I want to address those of you who have anxieties about @US_FDA's limited approval of a new mRNA COVID vaccine for high-risk populations. Moderna has agreed to a true placebo-controlled trial of the new vaccine....."

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) has outperformed the market over the past 5 years by 2.2% on an annualized basis producing an average annual return of 15.22%. Currently, Devon Energy has a market capitalization of $20.54 billion. 
Buying $1000 In DVN: If an investor had bought $1000 of DVN stock 5 years ago, it would be worth $2,192.47 today based on a price of $31.92 for DVN at the time of writing.
<h3>Devon Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748986211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Devon Energy Stock In The Last 5 Years

Recently disclosed clinical cohort data from high (1x1015&nbsp;total vg) and low dose (5.7x1014&nbsp;total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials
Caregiver research regarding gain/regain of developmental milestones supporting alignment with FDA on primary endpoint in the pivotal Part B trial of TSHA-102
Previously disclosed preclinical data supporting broad biodistribution across brain and spinal cord regions following lumbar intrathecal delivery of AAV9 gene therapy vectors in non-human primates
Symposium on Rett syndrome natural history data findings
DALLAS, June 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced details for three oral presentations reviewing recent updates supporting its TSHA-102 program in clinical evaluation for Rett syndrome, and a Taysha-hosted symposium on the Company's analysis of the natural history study data at the 2025 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting, taking place in&nbsp;Boston from&nbsp;June 9-11, 2025. The three presentations will also be presented during a poster session on Monday, June 9, 2025, from 5:00-7:00 PM EST. Additional details on the meeting can be found at IRSF's <a href="https://www.globenewswire.com/Tracker?data=fRcesPdJZ6naTCRmA1KdBnqknjMPiqUOSAZbibyIduSLIZBHD1sKDusevNNC9IDpOhcz49wKMcjwGxoZlu3UJQq_yJHoYjp2wi2ObKNmW3dZm0YC9_b3FmpZWcqr8vQ-RiqQI0N_8TElkfU9BZ2OAajR6CbuQwJ7QUjVqGCV5og=">website</a>.

Biotech

TSHA

Taysha Gene Therapies To Present Clinical And Preclinical Data Supporting TSHA-102 Rett Syndrome Program, Including Dose Cohort Results, Caregiver Insights Aligning With FDA Endpoints, At IRSF Scientific Meeting June 9–11, 2025 In Boston

LUCD

Lucid Diagnostics Files For Offering Of 36M Shares Of Common Stock

Lumentum Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) shares are rising in extended trading on Tuesday after the company updated its guidance for the current quarter ahead of a <a href="https://www.benzinga.com/topic/bofa">scheduled presentation this week</a>.
What Happened: After the market close on Tuesday, Lumentum said it now expects fourth-quarter revenue of $465 million to $475 million, up from prior guidance of $440 million to $470 million.
The company noted that it expects to achieve $500 million of revenue in the first quarter of fiscal 2026, a quarter earlier than previously planned. 
Lumentum also raised its fourth-quarter earnings guidance from a range of 70 cents to 80 cents per share to a new range of 78 cents to 85 cents per share. The company said it anticipates a fourth-quarter operating margin of 14% to 15%, up from prior guidance of 13% to 14%.
Lumentum&#8217;s management team will discuss the updated forecast at the BofA Securities 2025 Global Technology Conference&nbsp;on Wednesday. 
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45759307/sportsmans-warehouse-stock-tanks-after-q1-earnings-revenues-miss-details">Sportsman&#8217;s Warehouse Stock Tanks After Q1 Earnings, Revenues Miss: Details</a>
<h1 class="wp-block-heading">How To Buy LITE Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For Lumentum, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
LITE Price Action: Lumentum shares were up 3.67% in after-hours, trading at $80.50 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Guidance

LITE

Lumentum Stock Jumps After The Close On Rosier Outlook

Unitil Corp Files For Stock Shelf; Size Not Disclosed

Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) has outperformed the market over the past 5 years by 37.8% on an annualized basis producing an average annual return of 50.82%. Currently, Axon Enterprise has a market capitalization of $59.09 billion. 
Buying $100 In AXON: If an investor had bought $100 of AXON stock 5 years ago, it would be worth $818.05 today based on a price of $759.07 for AXON at the time of writing.
<h3>Axon Enterprise's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748985312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXON

$100 Invested In Axon Enterprise 5 Years Ago Would Be Worth This Much Today

Earnings

Press Releases

iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results

iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of  Zio® Long-Term Continuous Monitoring for Arrhythmia Detection

Turing Medical Names Transformative Med Tech Leader Kevin King as President and Chief Executive Officer

iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability

iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025

Health Care

iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring

iRhythm Technologies to Present at the Bank of America Securities 2025 Health Care Conference

iRhythm Technologies Announces First Quarter 2025 Financial Results

iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection

Comments

iRhythm Technologies

ニュース

パートナーシップ

ベンジンガ・グローバル